Impact of neoadjuvant cetuximab on liver function and tumor reduction in a murine model of selective portal vein ligation.

Concerning the RPML, the difference in tumor size between the vehicle-treated and cetuximab-treated groups was highly significant, since the vehicle-treated group had twice the tumor volume of the cetuximab-treated group (1.12 ± 0.45 vs. 0.53 ± 0.16 ml; p < 0.01) (shown in Fig. 6 B).

also in 132,142 other papers